Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 12 selected

Guidance programme

Showing 1 to 10 of 1253

TitleReference numberPublishedLast updated
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopauseTA1143
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophilsTA1142
Fetal monitoring in labourNG229
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1140
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)TA1141
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatmentTA1139
Pegzilarginase for treating arginase-1 deficiency in people 2 years and overHST35
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerTA1138
Hypertension in adults: diagnosis and managementNG136
Blood transfusionNG24

Results per page

  1. 10
  2. 25
  3. 50
  4. All